Yin, Jiale, Author at MediaMedic

$Orelabrutinib for the Treatment of Relapsed or Refractory Marginal Zone Lymphoma: A Phase 2 Study$

Orelabrutinib for the Treatment of Relapsed or Refractory Marginal Zone Lymphoma: A Phase 2 Study

By Yin, Jiale 2024.02.07

In November 2023, a study led by Professor Jun Zhu from Peking University Cancer Hospital and Institute was published in the prestigious international academic journal ——American Journal of Hematology (IF=12.8). The title of…

$Long-term Survival Benefit of Anti-PD-1 Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma$

Long-term Survival Benefit of Anti-PD-1 Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

By Yin, Jiale 2024.02.07

In September 2023, a study led by Professor Jun Zhu from Peking University Cancer Hospital and Institute was published in the prestigious international academic journal ——Signal Transduction and Targeted Therapy (IF=38.12). The title…

Unlocking the Cure: A Groundbreaking Study on ENKTCL Treatment Success Rates and Implications

By Yin, Jiale 2024.02.07

In September 2023, a retrospective multicentric study led by Professor Jun Zhu from Peking University Cancer Hospital and Institute was published in the prestigious international academic journal ——Haematologica (IF=11.047). The title of the study…

Professor SiZhou Feng : The Application of mNGS in Hematological Infections and the Optimization of Empirical Treatment Plans for Neutropenia-Associated Fever

By Yin, Jiale 2024.01.26

Editor's Note: At the recently held Fourth China Hematology Development Conference, the "Chinese Expert Consensus on the Application of Metagenomic Next-Generation Sequencing (mNGS) in the Diagnosis of Infectious Pathogens in…

Multidisciplinary Perspective: Professor MingGui Wang Shares Insights on the Application of mNGS in Blood Disease Infection Detection and Progress in Global CRO New Drug Treatment

By Yin, Jiale 2024.01.26

Editor's Note: In recent years, the problem of drug resistance has intensified, and carbapenem-resistant organisms (CRO), representing multiple drug-resistant bacteria, have imposed a significant disease burden globally. Patients with blood diseases…

Major Announcement! Top 10 Research Advances in Chinese Hematology in 2023 Revealed

By Yin, Jiale 2024.01.26

On January 7th, the Fourth Chinese Hematology Development Conference unveiled the "Top 10 Research Advances in Chinese Hematology in 2023." The selection of the "Top 10 Research Advances in Chinese…

2024 CASH | Professor ZhiJian Xiao : Breaking Through Tradition, Marching Towards the Future, The Perfect Integration of Precision Diagnosis and Digital Science

By Yin, Jiale 2024.01.26

The diagnosis of hematologic diseases has transitioned from traditional morphology-based methods to molecular diagnostics. Simultaneously, the treatment of these diseases has also moved from traditional chemotherapy to precision therapy, particularly…

Posts by Yin, Jiale

Orelabrutinib for the Treatment of Relapsed or Refractory Marginal Zone Lymphoma: A Phase 2 Study

Long-term Survival Benefit of Anti-PD-1 Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Unlocking the Cure: A Groundbreaking Study on ENKTCL Treatment Success Rates and Implications

Professor SiZhou Feng : The Application of mNGS in Hematological Infections and the Optimization of Empirical Treatment Plans for Neutropenia-Associated Fever

Multidisciplinary Perspective: Professor MingGui Wang Shares Insights on the Application of mNGS in Blood Disease Infection Detection and Progress in Global CRO New Drug Treatment

Major Announcement! Top 10 Research Advances in Chinese Hematology in 2023 Revealed

2024 CASH | Professor ZhiJian Xiao : Breaking Through Tradition, Marching Towards the Future, The Perfect Integration of Precision Diagnosis and Digital Science

2024 CASH | Professor XiaoFan Zhu : Immunotherapy Strategy Brings Greater Benefits to Children with ALL

2024 CASH丨Professor RongFu : Progress in the Study of Hematological Toxicity Related to CAR-T Therapy

2024 CASH | Professor LuGui Qiu : Continuous Advances in New Drugs, The Road to Cure Multiple Myeloma is Being Realized